Human Trials
Clinical trials of tigilanol tiglate use strict inclusion and exclusion criteria to identify patients most likely to respond safely, shaping the evidence base for EBC-46 research.
EBC-46
Modern EBC-46 trials track immune activation markers, vascular disruption signatures, and PKC pathway biomarkers — not just tumour volume.
EBC-46
EBC-46's ability to convert immunologically cold tumours into hot ones makes it a compelling partner for checkpoint blockade — here is the biology and the trial rationale.
EBC-46
EBC-46 lights the immune fire with acute local tumour antigen release. Checkpoint inhibitors remove the suppressors trying to extinguish it. The combination rationale is mechanistically sound.
EBC-46
The first-in-human Phase I trial of tigilanol tiglate demonstrated localised anti-tumour responses with a clean systemic safety profile — a result that immediately distinguished EBC-46 from prior PKC-targeting drugs.
EBC-46
Modern EBC-46 trials are incorporating biomarker endpoints that capture immune activation, vascular disruption, and tissue remodelling — painting a richer picture than tumour size alone.
EBC-46
Determining the right intratumoral dose of tigilanol tiglate required solving problems unique to locally-delivered agents — from volume calculation to defining dose-limiting toxicity at the injection site.
EBC-46
By triggering rapid local immune activation, tigilanol tiglate may prime the tumour microenvironment for checkpoint inhibitor therapy — a combination strategy now attracting serious clinical investigation.
EBC-46
Phase II trials targeting cutaneous head and neck squamous cell carcinoma with intratumoral tigilanol tiglate show measurable responses in accessible lesions and a well-characterised safety profile.
EBC-46
The biomarkers chosen for EBC-46 trials are not arbitrary — they reflect the current scientific understanding of how tigilanol tiglate kills tumours. Here's what researchers are measuring and why it matters.
EBC-46
Not every cancer patient qualifies for EBC-46 clinical trials. Tumour accessibility, prior treatment history, and lesion characteristics all determine eligibility — here is what the inclusion criteria reveal.
EBC-46
Phase I human trials of tigilanol tiglate are evaluating safety in solid tumours. Early data suggests the tolerability profile mirrors what was observed in veterinary studies.